Routine voluntary antepartum HIV antibody counseling and testing: A sound public health prevention strategy

Clinical Obstetrics and Gynecology

Volumn 39, Issue 2, 1996, Pages 305-315

  Lindsay, Michael K ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DETECTION; CLINICAL PROTOCOL; DIAGNOSTIC VALUE; FEMALE; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; INFORMED CONSENT; MEDICAL DECISION MAKING; PATIENT COUNSELING; PRENATAL SCREENING; PREVENTIVE HEALTH SERVICE; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; UNITED STATES;

ANONYMOUS TESTING; AZT; CENTERS FOR DISEASE CONTROL AND PREVENTION; CLINICAL APPROACH/SOURCE; FEDERAL GOVERNMENT; HEALTH CARE AND PUBLIC HEALTH; PREGNANT WOMEN; UNITED STATES; VOLUNTARY PROGRAMS;

ANONYMOUS TESTING; DISEASE TRANSMISSION, VERTICAL; FEDERAL GOVERNMENT; FEMALE; FORECASTING; GUIDELINES; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MASS SCREENING; PATIENT EDUCATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANT WOMEN; PRENATAL CARE; RESEARCH; RISK FACTORS; VOLUNTARY PROGRAMS;

EID: 0029920019     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199606000-00006     Document Type: Review

References (59)

1. Chin J. Current and future dimensions of the HIV/AIDS pandemic in women and children. Lancet. 1991;336:221-224.
2. Centers for Disease Control and Prevention. Update: AIDS among women - United States 1994. MMWR. 1995;44:81-84.
3. Oxtoby M. Vertically acquired HIV infection in the U.S. In: Pizzo PA, Wilbert CM, eds. Pediatric AIDS: The challenge of HIV Infection in Infants, Children and Adolescents, 2nd ed. Baltimore: Williams & Wilkins, 1994:3-20.
4. Conner EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. N Engl J Med. 1994;337:1173-1180.
5. Lindsay MK, Feng TI, Peterson HB, et al. Routine antepartum human immunodeficiency virus infection screening in an inner-city population. Obstet Gynecol. 1989;74: 289-294.
6. Barbacci MB, Repke JT, Chaisson RE. Routine prenatal screening for HIV infection. Lancet. 1991;337:709-711.
7. Cozen W, Mascola L, Enguidanos R, et al. Screening for HIV and Hepatitis B virus in Los Angeles County Prenatal Clinics: a demonstration project. J AIDS. 1993;6: 95-98.
8. Stratton P, Mofenson LM, Willoughby A. Human immunodeficiency virus infection in pregnant women under care at AIDS Clinical Trials Centers in the United States. Obstet Gynecol. 1992;79:364-368.
9. Wortley PM, Chu SY, Diaz T, et al. HIV testing patterns: where, why and when were persons with AIDS tested for HIV? AIDS. 1995;9:487-492.
10. Centers for Disease Control and Prevention. Recommendations for assisting in the prevention of perinatal transmission of HTLV-III/LAV and acquired immunodeficiency syndrome. MMWR. 1985;34:721-732.
11. Sachs BP, Tuomala R, Frigoletto F. Acquired immunodeficiency syndrome suggested protocol for counseling and screening in pregnancy. Obstet Gynecol. 1987;70:408-411.
12. Minkoff HL, Landesman SH. The case for routinely offering prenatal testing for human immunodeficiency virus. Am J Obstet Gynecol. 1988;159:793-796.
13. Bayer R, Levine C, Wolf S. HIV antibody screening an ethical framework for evaluating proposed programs. JAMA. 1986;256: 1768-1774.
14. Barbacci MB, Dalabetta GA, Repke JT, et al. Human immunodeficiency virus infection in women attending an inner-city prenatal clinic: ineifectiveness of targeted screening. Sex Trans Dis. 1990;Jul-Sept: 122-126.
15. Fehrs LJ, Hill D, Kerndt PR, et al. Targeted HIV screening at a Los Angeles prenatal family planning health center. Am J Public Health. 1991;81:619-622.
16. Landesman S, Minkoff H, Holman S, et al. Serosurvey of human immunodeficiency virus infection in parturients. JAMA. 1987; 258:2701-2703.
17. Sperling RS, Sack HS, Mayer L, et al. Umbilical cord blood serosurvey for human immunodeficiency virus in parturient women in a voluntary hospital in New York City. Obstet Gynecol. 1989;73:179-181.
18. Hoff RH, Berardi VP, Weiblen BJ, et al. Seroprevalence of human immunodeficiency virus among childbearing women estimation by testing samples of blood from newborns. N Engl J Med. 1988;318:525-530.
19. Novick LF, Berns D, Stricof R, et al. HIV seroprevalence in newborns in New York State. JAMA. 1989;261:1745-1750.
20. Gwinn M, Pappaionou M, George R, et al. Prevalence of HIV infection in childbearing women in the United States. JAMA. 1991;265:1704-1708.
21. Wilfert CM. Mandatory screening of pregnant women for the human immunodeficiency virus. Clin Infect Dis. 1994;19:664-666.
22. Parks W. Point/Counterpoint: HIV-1 screening of pregnant women. Obstet and Gynecol Survey. 1995;50:1-2.
23. Keut C. HIV testing of pregnant women, newborns debated. American Medical News. 1995:6.
24. Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med. 1995;333:401-407.
25. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary Human Immunodeficiency Virus Infection. N Engl J Med. 1995;333:408-413.
26. Lindsay MK. A protocol for routine voluntary antepartum HIV screening. Am J Obstet Gynecol. 1993;168:476-479.
27. Hein K. Mandatory HIV testing of youth. A lose-lose proposition. JAMA. 1991;266: 2430-2431.
28. Minkoff H. Point/Counterpoint: the case against mandatory prenatal HIV testing. Obstet and Gynecology Survey. 1995;50: 2-3.
29. Rhame FS, Maki DG. The case for wider use of testing for HIV infection. N Engl J Med. 1989;320:1248-1253.
30. Antiretroviral therapy and medical management of the HIV-infected child working group on antiretroviral therapy: National Pediatric HIV Resource Center. Pediatric Infect Dis J. 1993;12:1513-1521.
31. American College of Obstetricians and Gynecologists. Human immunodeficiency virus infection, Technical Bulletin No 165. Washington; ACOG, 1992.
32. Task Force on Pediatric AIDS perinatal human immunodeficiency virus testing. Pediatrics. 1992;89:791-794.
33. Hardy LM. HIV screening of pregnant women and newborns. Washington, D.C.: National Academy Press, 1991.
34. HIV infection pregnant women and newborns. A policy proposal for information and testing. JAMA. 1990;264:2416-2420.
35. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR. 1995;44:1-14.
36. Risby J, Carey S, Lindsay M. The effectiveness of HIV counseling on retention of knowledge in an inner-city prenatal population. Am J Obstet Gynecol. 1995;172: 307.
37. Higgins DL, Galavotti C, O'Reilly KR et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA. 1991;266:2419-2429.
38. Lindsay MK, Feng TI, Peterson HB, et al. Routine human immunodeficiency virus infection screening in unregistered and registered inner-city parturients. Obstet Gynecol. 1991;77:599-603.
39. Lindsay MK, Grant J, Peterson H, et al. The impact of knowledge of human immunodeficiency virus serostatus on contraceptive choice and repeat pregnancy. Obstet Gynecol. 1995;85:675-679.
40. Centers for Disease Control and Prevention. Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. MMWR. 1987;36:509-515.
41. Cates W, Toomey KE, Hanlak GR, et al. Partner notification and confidentiality of the index patient: its role in preventing HIV. Sex Trans Dis. 1990;17:113-114.
42. Landis SE, Schoenbach VJ, Weber DJ. Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. N Engl J Med. 1992;326:101-106.
43. North R, Rothenberg KH. Partner notification and the threat of domestic violence against women with HIV infection. N Engl J Med. 1993;329:1194-1196.
44. Selwyn PA, Schoenbaum EE, Davenny K, et al. Prospective study of human immunodeficiency virus infection and pregnancy outcomes in intravenous drug users. JAMA. 1989;261:1289-1294.
45. Minkoff HL, Henderson C, Mendez H, et al. Pregnancy outcomes among mothers infected with human immunodeficiency virus and uninfected control subjects. Am J Obstet Gynecol. 1990;163:1598-1604.
46. Geary FH, Lindsay MK, Graves WL, et al. HIV infection is not a risk factor for adverse perinatal outcome. J Maternal Fetal Med. 1995;4:29-34.
47. Alger LS, Farley JJ, Robinson BA, et al. Interactions of human immunodeficiency virus infection and pregnancy. Obstet Gynecol. 1993;82:787-796.
48. Hutto C, Parks WP, Lai SH, et al. A hospital-based prospective study of perinatal infection with human immunodeficiency virus type 1. J Pediatr. 1991;118:347-353.
49. Nair P, Alger L, Hines S, et al. Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J AIDS. 1993;6:298-302.
50. Boyer PJ, Dillon M, Nanaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1. JAMA. 1994;271:1923-1930.
51. Mofenson LM. Epidemiology and determinants of vertical HIV transmission. Seminars in Pediatric Infectious Diseases. 1994;4:252-265.
52. Sperling RS, Stratton P, O'Sullivan MJ, et al. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. N Engl J Med. 1992;326:857-861.
53. Centers for Disease Control and Prevention. Birth outcomes following zidovudine therapy in pregnant women. MMWR. 1994;43: 415-416.
54. Centers for Disease Control and Prevention. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR. 1994; 43(RR-11).
55. Sunderland A, Minkoff H, Handte J, et al. The impact of human immunodeficiency virus serostatus on reproductive decision of women. Obstet Gynecol. 1992;79:1027-1031.
56. El-Sadr W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, January 1994. DHHS publication no. (AHCPR) 94-0572.
57. Centers for Disease Control and Prevention. Risk for cervical disease in HIV-infected women-New York City. MMWR. 1990;39: 846-849.
58. Maiman M, Tarricone N, Viera J, et al. Colposcopic evaluation of human immunodeficiency virus-seropositive women. Obstet Gynecol. 1991;78:84-88.
59. Valdiserri RO, Moore M, Gerber RA, et al. A study of clients returning for counseling after HIV testing implications for improving rates of return. Public Health Report. 1993;108:12-18.